Fennec Pharmaceuticals Inc. held its Annual General and Special Meeting of Shareholders on June 3, 2025. During the meeting, the election of directors was approved. Additionally, the appointment of Haskell & White LLP as auditors and the authorization for directors to fix the auditor remuneration were approved. Certain amendments to the 2020 Equity Incentive Plan were also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.